ArticleACS central science2016
pH-Sensitive Pt Nanocluster Assembly Overcomes Cisplatin Resistance and Heterogeneous Stemness of Hepatocellular Carcinoma.
Article in ACS central science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Dual-Targeting CSC Therapy: Acid-Responsive Cisplatin/CaCOPharmaceuticals (Basel, Switzerland) · 2025Article
- Innovative Approaches to Enhancing the Biomedical Properties of Liposomes.Pharmaceutics · 2024Review
- Stimuli-responsive peptide assemblies: Design, self-assembly, modulation, and biomedical applications.Bioactive materials · 2024Review
- Metal nanoparticles for cancer therapy: Precision targeting of DNA damage.Acta pharmaceutica Sinica. B · 2024Review
- Liposomes for Tumor Targeted Therapy: A Review.International journal of molecular sciences · 2023Review
- Cytotoxic sub-nanometer aqueous platinum clusters as potential antitumoral agents.Nanoscale advances · 2022Article
- A nuclease-mimetic platinum nanozyme induces concurrent DNA platination and oxidative cleavage to overcome cancer drug resistance.Nature communications · 2022Article
- Mitochondrial fission factor promotes cisplatin resistancein hepatocellular carcinoma.Acta biochimica et biophysica Sinica · 2022Article
- Platinum-based drugs for cancer therapy and anti-tumor strategies.Theranostics · 2022Review
- Synergistic enhancement of immunological responses triggered by hyperthermia sensitive Pt NPsBioactive materials · 2022Article
- Light-activated nanomaterials for tumor immunotherapy.Frontiers in chemistry · 2022Review
- Magnetic Nanomaterials for Arterial Embolization and Hyperthermia of Parenchymal Organs Tumors: A Review.Nanomaterials (Basel, Switzerland) · 2021Review
- Synergistic integration of metal nanoclusters and biomolecules as hybrid systems for therapeutic applications.Acta pharmaceutica Sinica. B · 2021Review
- Biomimetic Liposomal Nanoplatinum for Targeted Cancer Chemophototherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Platinum-Induced Peripheral Neuropathy (PIPN): ROS-Related Mechanism, Therapeutic Agents, and Nanosystems.Frontiers in molecular biosciences · 2021Review
- Soft and Condensed Nanoparticles and Nanoformulations for Cancer Drug Delivery and Repurpose.Advanced therapeutics · 2020Article
- Silicon Nanotubes as Potential Therapeutic Platforms.Pharmaceutics · 2019Review
- Injectable peptide hydrogel as intraperitoneal triptolide depot for the treatment of orthotopic hepatocellular carcinoma.Acta pharmaceutica Sinica. B · 2019Article
- Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3η/NF-κB feedback loop.Journal of experimental & clinical cancer research : CR · 2018Article
- Overcoming Ovarian Cancer Drug Resistance with a Cold Responsive Nanomaterial.ACS central science · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Response rates to conventional chemotherapeutics remain unsatisfactory for hepatocellular carcinoma (HCC) due to the high rates of chemoresistance and recurrence. Tumor-initiating cancer stem-like cells (CSLCs) are refractory to chemotherapy, and their enrichment leads to subsequent development of chemoresistance and recurrence. To overcome the chemoresistance and stemness in HCC, we synthesized a Pt nanocluster assembly (Pt-NA) composed of assembled Pt nanoclusters incorporating a pH-sensitive polymer and HCC-targeting peptide. Pt-NA is latent in peripheral blood, readily targets disseminated HCC CSLCs, and disassembles into small Pt nanoclusters in acidic subcellular compartments, eventually inducing damage to DNA. Furthermore, treatment with Pt-NA downregulates a multitude of genes that are vital for the proliferation of HCC. Importantly, CD24+ side population (SP) CSLCs that are resistant to cisplatin are sensitive to Pt-NA, demonstrating the immense potential of Pt-NA for treating chemoresistant HCC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.